Spyre Therapeutics (FRA:3920) Days Payable: 0.00 (As of Mar. 2026)

What is Spyre Therapeutics Days Payable?

Spyre Therapeutics FRA:3920 -2.56% 31 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates FRA:3920 with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 700 Biotechnology companies, Spyre Therapeutics ranks worse than 142857% on this metric.

Spyre Therapeutics's average Accounts Payable for the three months ended in Mar. 2026 was €6.26 Mil. Spyre Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2026 was €0.00 Mil.

The historical rank and industry rank for Spyre Therapeutics's Days Payable or its related term are showing as below:

FRA:3920's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 113.1
* Ranked among companies with meaningful Days Payable only.

Spyre Therapeutics's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

Spyre Therapeutics Days Payable Related Terms

Spyre Therapeutics Days Payable Historical Data

* Premium members only.

The historical data trend for Spyre Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spyre Therapeutics Days Payable Chart

Spyre Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Days Payable

Get a 7-Day Free Trial

0.00

Spyre Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Days Payable	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

FRA:3920 vs MIRM, RYTM, PTGX: Days Payable Comparison

For the Biotechnology subindustry, Spyre Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spyre Therapeutics Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Spyre Therapeutics's Days Payable falls into.

Save Embed

31GF Score

Spyre Therapeutics Inc FRA:3920

Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Spyre Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Spyre Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

	Days Payable (A: Dec. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2024 )	+	Accounts Payable (A: Dec. 2025 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2025 )	*	Days in Period
=	( (0.636	+	7.604)	/	2 )	/	0	*	365
=	4.12					/	0	*	365
=	N/A

Spyre Therapeutics's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

	Days Payable (Q: Mar. 2026 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2025 )	+	Accounts Payable (Q: Mar. 2026 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
=	( (7.604	+	4.924)	/	2 )	/	0	*	365 / 4
=	6.264					/	0	*	365 / 4
=	N/A

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 0.00 mean?

Spyre Therapeutics (FRA:3920) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Spyre Therapeutics and its competitors. According to the industry distribution chart, Spyre Therapeutics ranks #999999 out of 700 companies in the Biotechnology industry.

Is Spyre Therapeutics' Days Payable too high?

Spyre Therapeutics' current Days Payable is 0.00. Based on the distribution chart, Spyre Therapeutics ranks #999999 out of 700 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Spyre Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.

How does Spyre Therapeutics' Days Payable compare to MIRM and RYTM?

According to the Biotechnology industry distribution chart, Spyre Therapeutics ranks #999999 out of 700 companies for Days Payable. This places Spyre Therapeutics in the lower half of its industry. The industry median Days Payable is 113.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Biotechnology company?

The median Days Payable among Biotechnology companies is 113.10, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Spyre Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spyre Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Spyre Therapeutics stock overvalued right now?

Spyre Therapeutics (FRA:3920) has a current Days Payable of 0.00. The current Days Payable is 0.00. Spyre Therapeutics' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For Spyre Therapeutics (FRA:3920), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Spyre Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies MIRM RYTM PTGX IMVT PCVX PTCT TGTX SRRK COGT CGON VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges SYRE:USA 3920:Germany

Address 221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453

Website https://www.spyre.com

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

31GF Score

Get the complete analysis for FRA:3920

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€76.00

Price

View FRA:3920 Analysis

See Days Payable data for all stocks →